- Home
- ITCI vs CHE Comparison
ITCI vs CHE Comparison
Compare ITCI & CHE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ITCI
- CHE
- Stock Information
- Founded
- ITCI 2002
- CHE 1970
- Country
- ITCI United States
- CHE United States
- Employees
- ITCI N/A
- CHE N/A
- Industry
- ITCI Biotechnology: Pharmaceutical Preparations
- CHE Medical/Nursing Services
- Sector
- ITCI Health Care
- CHE Health Care
- Exchange
- ITCI Nasdaq
- CHE Nasdaq
- Market Cap
- ITCI 8.0B
- CHE 9.0B
- IPO Year
- ITCI N/A
- CHE N/A
- Fundamental
- Price
- ITCI $76.91
- CHE $593.84
- Analyst Decision
- ITCI Strong Buy
- CHE Buy
- Analyst Count
- ITCI 12
- CHE 2
- Target Price
- ITCI $97.00
- CHE $673.50
- AVG Volume (30 Days)
- ITCI 438.6K
- CHE 76.0K
- Earning Date
- ITCI 10-30-2024
- CHE 10-29-2024
- Dividend Yield
- ITCI N/A
- CHE 0.34%
- EPS Growth
- ITCI N/A
- CHE 31.50
- EPS
- ITCI N/A
- CHE 19.72
- Revenue
- ITCI $564,526,000.00
- CHE $2,335,557,000.00
- Revenue This Year
- ITCI $46.60
- CHE $8.90
- Revenue Next Year
- ITCI $37.06
- CHE $7.70
- P/E Ratio
- ITCI N/A
- CHE $30.23
- Revenue Growth
- ITCI 54.31
- CHE 6.79
- 52 Week Low
- ITCI $45.50
- CHE $502.64
- 52 Week High
- ITCI $84.89
- CHE $654.62
- Technical
- Relative Strength Index (RSI)
- ITCI 57.52
- CHE 50.70
- Support Level
- ITCI $71.95
- CHE $585.06
- Resistance Level
- ITCI $79.46
- CHE $615.65
- Average True Range (ATR)
- ITCI 1.79
- CHE 11.16
- MACD
- ITCI 0.49
- CHE 0.05
- Stochastic Oscillator
- ITCI 70.25
- CHE 51.48
About ITCI Intra-Cellular Therapies Inc.
Intra-Cellular Therapies Inc is a biopharmaceutical company that develops novel drugs for treating diseases of the central nervous system. The company is focused on the delivery and clinical development of small-molecule drugs that address needs in neuropsychiatric and neurological disorders. Intra-Cellular maintains proprietary chemistry platforms to develop drugs for neurodegenerative diseases. The company's business segment is discovering and developing drugs for the treatment of neurological and psychiatric disorders.
About CHE Chemed Corp
Chemed Corp operates subsidiaries in two main segments: VITAS and Roto-Rooter. The VITAS segment generates the majority of the firm's revenue. It provides hospice and palliative care services to patients with terminal illnesses through a network of physicians, registered nurses, home health aides, social workers, and volunteers. The vast majority of the segment's revenue is received from the Medicare and Medicaid reimbursement programs. The Roto-Rooter segment provides plumbing, drain cleaning, water restoration, and related services to residential and commercial customers. Chemed generates the majority of its revenue from business in the United States.